Table 2.
Age-Standardized Patient Demographic and Clinicopathologic Characteristics According to Race/Ethnicity: 2000 to 2007
| Characteristic | White (n = 14,268) | Hispanic (n = 1,122) | Black (n = 1,345) | Asian (n = 533) | P* |
|---|---|---|---|---|---|
| Length of follow-up, years | < .001 | ||||
| Median | 6.3 | 6.0 | 5.7 | 6.2 | |
| SD | 2.4 | 2.3 | 2.5 | 2.3 | |
| Age at diagnosis, years† | < .001 | ||||
| Mean | 55.2 | 52.0 | 53.5 | 51.1 | |
| SD | 11.7 | 3.8 | 4.3 | 2.6 | |
| Detection with symptoms, % | 53.6 | 64.3 | 63.4 | 67.3 | < .001 |
| AJCC stage, % | < .001 | ||||
| I | 45.6 | 34.0 | 32.1 | 40.0 | |
| II | 40.7 | 44.8 | 43.8 | 45.0 | |
| III | 13.7 | 21.1 | 24.1 | 14.9 | |
| ER positive, % | 76.1 | 72.8 | 59.6 | 72.3 | < .001 |
| HER2 overexpressed, % | 16.8 | 20.1 | 18.8 | 20.6 | .04 |
| High tumor grade, % | 43.0 | 50.5 | 64.6 | 42.4 | < .001 |
| Molecular phenotype, % | < .001 | ||||
| Luminal A like | 47.4 | 42.1 | 27.1 | 48.0 | |
| Luminal B like | 29.8 | 32.6 | 34.0 | 25.8 | |
| HER2 type | 7.0 | 8.2 | 9.3 | 10.9 | |
| Triple negative | 15.9 | 17.0 | 29.6 | 15.3 | |
| Chemotherapy, % | 68.0 | 80.1 | 78.1 | 72.2 | < .001 |
| Hormonal therapy, %‡ | 95.2 | 94.1 | 92.6 | 94.7 | .004 |
| Trastuzumab, %§ | 46.4 | 55.2 | 50.0 | 46.0 | .11 |
| Postmenopausal, % | 60.1 | 52.9 | 57.9 | 46.9 | < .001 |
| Comorbidity score ≥ 1, % | 20.2 | 22.4 | 30.2 | 16.3 | < .001 |
| BMI, kg/m2 | < .001 | ||||
| Mean | 27.5 | 28.5 | 31.5 | 23.9 | |
| SD | 6.0 | 2.2 | 2.8 | 1.0 | |
| Educational attainment, % | < .001 | ||||
| ≤ High school | 24.7 | 38.8 | 30.6 | 22.1 | |
| Some college | 22.0 | 19.0 | 25.9 | 12.7 | |
| College graduate | 20.3 | 13.6 | 13.0 | 28.4 | |
| Graduate school | 15.3 | 10.6 | 9.7 | 20.5 | |
| Insurance status, % | < .001 | ||||
| Managed care | 67.0 | 59.0 | 59.3 | 72.8 | |
| Medicare | 19.8 | 9.1 | 18.9 | 8.5 | |
| Medicaid or uninsured | 3.5 | 20.8 | 15.0 | 8.3 | |
| Other or unknown | 8.4 | 10.7 | 6.0 | 10.5 | |
| Employment status, % | < .001 | ||||
| Employed or student | 50.0 | 50.3 | 50.2 | 56.0 | |
| Homemaker or retired | 34.7 | 37.4 | 24.1 | 32.3 | |
| Unable to work, unemployed, or other | 15.3 | 12.3 | 25.7 | 11.8 |
Abbreviations: AJCC, American Joint Committee on Cancer; BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; SD, standard deviation.
*
Age-adjusted P values calculated using multinomial (categorical variables) or binomial logistic (binary variables) regression models.
†
Not age adjusted.
‡
Among women with ER-positive tumors only.
§
Among women with tumors that overexpressed HER2 only. Trastuzumab was indicated for adjuvant setting in 2006, so receipt of trastuzumab was lower for time period analyzed.